Key Takeaways
- MT1 (afamelanotide) is FDA-approved as Scenesse for erythropoietic protoporphyria; MT2 has no approved form in any jurisdiction.
- MT2's MC4R agonism drives erectile and libido effects absent in MT1, confirmed in a small but placebo-controlled human pilot (Wessells et al., 2000, n=10).
- MT2's cyclic lactam structure confers modestly greater solution stability than the linear MT1 backbone by reducing susceptibility to backbone hydrolysis, but both degrade meaningfully within days at room temperature once reconstituted.
- MT1 has multiple phase 3 RCTs in EPP; MT2's human evidence is almost entirely early-phase or uncontrolled, making it a lower-evidence compound for every claimed benefit.
- Neither compound has long-term human carcinogenicity data; melanocyte stimulation without UV-protective context raises unresolved safety questions for cosmetic use.
MT1 vs MT2: Direct Answer
MT1 (afamelanotide) is a selective MC1R agonist with approved clinical use and strong RCT tanning evidence. MT2 is a non-selective melanocortin agonist with added MC4R activity, producing erections and stronger nausea alongside tanning. MT2 has weaker human evidence and no regulatory approval. For pure photoprotective tanning, MT1 wins on evidence. For sexual function, MT2 is the only option, with modest pilot data.Table of Contents
- How are MT1 and MT2 structurally different?
- Which receptors does each peptide hit, and what does that mean?
- Evidence ledger: what does the research actually show?
- Which is better for tanning?
- Does MT2 really work for erections and libido?
- Side-effect comparison: honest and specific
- What most pages get wrong about MT1 vs MT2
- Stability, formulation, and the degradation problem
- Head-to-head comparison table
- Label literacy: how to evaluate a product or COA
- FAQ
- Sources
How Are MT1 and MT2 Structurally Different?
MT1 is afamelanotide, a linear 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its sequence is [Nle4, D-Phe7]-alpha-MSH. The substitution of norleucine at position 4 and D-phenylalanine at position 7 increases potency and resistance to enzymatic degradation compared to native alpha-MSH, but the peptide remains linear.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →MT2 is a cyclic 7-amino-acid lactam analog: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2. The cyclic lactam bridge between aspartate and lysine constrains the backbone conformation, locking the pharmacophore His-Phe-Arg-Trp into a geometry that fits multiple melanocortin receptors simultaneously. This cyclization is the single architectural decision that explains most of the differences between the two peptides.
The cyclization makes MT2 smaller by residue count, more conformationally rigid, and, as described below, less selective. It also contributes to modestly better aqueous stability compared to the linear MT1 backbone, primarily because removing a free amine terminus and constraining the backbone reduces susceptibility to hydrolytic cleavage.
Which Receptors Does Each Peptide Hit, and What Does That Mean?
There are five melanocortin receptors (MC1R through MC5R). Their tissue distribution determines what happens when you activate them.
| Receptor | Primary tissue location | MT1 activity | MT2 activity | Clinical consequence |
|---|---|---|---|---|
| MC1R | Melanocytes, skin | High (primary target) | High | Pigmentation, photoprotection |
| MC3R | Brain, gut, immune cells | Low | Moderate | Energy homeostasis, possibly anti-inflammatory (speculative) |
| MC4R | Hypothalamus, spinal cord | Negligible | High | Erectile function, appetite suppression, nausea |
| MC5R | Exocrine glands, skin | Low | Moderate | Sebum secretion (speculative human relevance) |
The practical takeaway: MT1 is a targeted MC1R agonist. MT2 is a broad melanocortin agonist. Every additional receptor MT2 hits is both a potential benefit and a source of side effects. The MC4R activity is why MT2 causes erections and nausea; MT1 essentially does not.
Evidence Ledger: What Does the Research Actually Show?
| Claim | Best evidence type | Representative source | Effect direction | Confidence |
|---|---|---|---|---|
| MT1 (afamelanotide) reduces phototoxic pain in EPP | Phase 3 RCT, n=93 and n=74 | Langendonk et al. 2015, NEJM | Positive, significant | High |
| MT1 increases skin pigmentation in healthy volunteers | Small RCTs and controlled studies | Minder et al. and others | Positive | Moderate |
| MT1 increases pigmentation in vitiligo | Phase 2 RCT | Lim et al. 2019 | Positive with NB-UVB | Moderate |
| MT2 produces erections in men | Placebo-controlled pilot, n=10 | Wessells et al. 2000, Urology | Positive (80% vs 17%) | Low to moderate (very small n) |
| MT2 causes tanning | Early-phase human studies, animal data | Various 1990s University of Arizona work | Positive directionally | Low |
| MT2 suppresses appetite or aids weight loss in humans | Mechanism only, animal models | MC4R KO mouse literature | Speculative in humans | Very low |
| MT2 increases female sexual arousal | Single small RCT (bremelanotide, a related compound) | Diamond et al. 2006 | Positive, modest | Low (different compound) |
| Either peptide causes melanoma in humans | Case reports, mechanistic concern only | MHRA warnings, Lim et al. | No causal data; theoretical risk | Very low (unresolved) |
Which Is Better for Tanning?
MT1 has the stronger controlled evidence for tanning because its trials were large enough and well-designed enough to measure colorimetric skin changes. The Langendonk et al. EPP trials used objective melanin index measurements and found statistically significant increases. MT1 tanning requires some UV exposure to convert pre-existing eumelanin stores; it primes the pathway rather than replacing UV entirely.
MT2 tanning claims originate largely from early open-label work at the University of Arizona in the 1990s, where subjects reported visible tanning with minimal UV exposure. These reports are real but not confirmed in phase 2 or 3 trials with colorimetric endpoints. The mechanism is plausible: MC1R agonism by MT2 is potent, and the cyclic structure may produce more prolonged receptor occupancy. But "plausible mechanism plus early reports" is not the same as controlled evidence.
Bottom line: if tanning is the primary goal and you want the best-evidenced compound, MT1 (afamelanotide) is the choice. MT2 may produce comparable or stronger tanning subjectively, but you cannot say that with the same confidence.
Does MT2 Really Work for Erections and Libido?
The most-cited human data come from Wessells et al. (2000), a double-blind crossover trial in 10 men with psychogenic erectile dysfunction. A single subcutaneous dose of 0.025 mg/kg MT2 produced clinically observed erections in 8 of 10 men (80%) versus 2 of 10 on placebo (17%). The effect began within 30 to 60 minutes and was accompanied by significant nausea in most participants.
The mechanism is MC4R agonism in hypothalamic paraventricular nucleus neurons, which project via oxytocinergic pathways to spinal erectile centers. This pathway is well-established in animal models and consistent with the human pilot data.
What this does NOT prove: efficacy in larger populations, organic erectile dysfunction, women as a primary population, or safety with repeated dosing. Bremelanotide (PT-141), a metabolite of MT2, received FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women (Vyleesi), which provides indirect confirmation of the MC4R pathway's relevance, but bremelanotide is a distinct compound with its own trial data.
MT1 has no meaningful human data for sexual function. Its MC1R selectivity means the MC4R pathway is not meaningfully engaged.
Side-Effect Comparison: Honest and Specific
| Side effect | MT1 (afamelanotide) | MT2 | Mechanism |
|---|---|---|---|
| Nausea | Mild, reported in a minority of EPP trial participants | Frequent at doses producing erectile effect; majority of participants in Wessells 2000 | MC4R and possibly MC3R activation in area postrema |
| Spontaneous erections | Not reported at clinical doses | Common at erectogenic doses | MC4R hypothalamic-spinal pathway |
| Flushing | Reported in EPP trials | Reported | Peripheral vasodilation, MC1R and MC3R |
| Darkening of existing nevi | Reported; regulatory monitoring required | Reported; MHRA warning | MC1R-driven melanocyte activation in pre-existing nevi |
| Injection site reactions | Common with subcutaneous implant | Common with subcutaneous injection | Local tissue response |
| Fatigue or yawning | Rare | Reported; likely central MC4R | Central melanocortin activity |
| New pigmented lesions | Under surveillance in EPP trials; causality unestablished | Case reports; causality unestablished | Melanocyte proliferation concern |
What Most Pages Get Wrong About MT1 vs MT2
1. Treating MT2 as "stronger MT1." MT2 is not simply a more potent version of MT1. It is a pharmacologically distinct compound with a different receptor fingerprint. The comparison is closer to comparing a selective beta-1 blocker to a non-selective beta blocker. You do not get "more tanning with extra benefits." You get a different drug with different risk terrain.
2. Citing the Wessells erection data as if it proves routine use. Ten men in a single-dose crossover study is a pilot. It establishes a signal, not efficacy for a population. Every site that says "MT2 works for ED" should say "a small pilot suggests a signal; larger trials were not pursued for MT2 itself."
3. Ignoring purity and sourcing as a safety variable. Commercially available "research" MT2 from unverified suppliers has unknown purity, unknown peptide content, and no pharmacovigilance. The risks reported in case literature are not purely pharmacological; they include reactions to impurities and incorrect dosing from inaccurate labeling. This is not a minor caveat.
4. Conflating bremelanotide data with MT2 data. Bremelanotide (PT-141) is a cyclic heptapeptide metabolite of MT2. Its FDA-approved Vyleesi indication does not validate MT2 itself. They are related but distinct compounds with different pharmacokinetic profiles and separate trial programs.
Stability, Formulation, and the Degradation Problem
Both peptides are susceptible to two main degradation pathways: oxidation and hydrolysis.
Oxidation: The tryptophan residue (Trp) in both peptides is vulnerable to oxidative degradation, particularly in the presence of dissolved oxygen, light, or metal ions. This converts Trp to N-formylkynurenine and related species, destroying biological activity. A solution that has turned yellow-brown has undergone this transformation.
Hydrolysis: Peptide bonds cleave in aqueous solution at a rate that increases with temperature and extreme pH. MT2's cyclic lactam bridge removes one free amine terminus and constrains the backbone, which reduces susceptibility to hydrolytic cleavage compared to the linear MT1 chain. This is a real but modest stability advantage for MT2 in solution. Exact kinetic constants for both peptides under physiologic conditions are not well-published in accessible literature; avoid any vendor who gives you precise stability half-life numbers without citing a source.
Practical storage rules with the chemistry behind them:
- Keep lyophilized powder at 2 to 8 degrees Celsius. Below 0 Celsius is not harmful for the powder but freeze-thaw cycles introduce moisture, which initiates hydrolysis. The fridge, not the freezer, is the correct target for routine storage.
- Reconstitute with bacteriostatic water, not plain sterile water. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth. This matters because peptide solutions support bacterial growth and contamination is a separate source of degradation and patient harm.
- Use reconstituted solution within days, kept at 2 to 8 degrees Celsius. Once in solution, oxidation accelerates. There is no widely accepted published stability period for either peptide in aqueous solution at body temperature; days is conservative and appropriate.
- Protect from light. Photodegradation is a real pathway for Trp-containing peptides. Amber vials and avoiding direct light are not marketing theater.
Head-to-Head Comparison Table
| Parameter | MT1 (Afamelanotide) | MT2 | Winner (honest) |
|---|---|---|---|
| Structure | Linear 13-mer | Cyclic 7-mer lactam | Tie (context-dependent) |
| Primary receptor | MC1R selective | MC1R, MC3R, MC4R, MC5R | MT1 for selectivity; MT2 for breadth |
| Tanning evidence quality | Multiple RCTs, colorimetric endpoints | Early-phase, subjective reports | MT1 |
| Sexual function | No meaningful data | Pilot RCT signal (Wessells 2000) | MT2 (weak evidence) |
| Regulatory status | FDA-approved (EPP, implant form) | No approval anywhere | MT1 decisively |
| Nausea burden | Mild, minority of users at clinical doses | Frequent at erectogenic doses | MT1 |
| Solution stability | Lower (linear backbone more susceptible to hydrolysis) | Modestly higher (cyclic lactam reduces hydrolytic cleavage) | MT2 (minor advantage) |
| Sourcing safety (research market) | Same purity risk as MT2 from unverified sources | Same purity risk; more adverse event reports | Neither (both problematic) |
| Long-term safety data | Phase 3 and post-marketing (EPP population) | Absent | MT1 |
| Closest approved analog | Afamelanotide (Scenesse) | Bremelanotide (Vyleesi) | MT1 (direct approval) |
Label Literacy: How to Evaluate a Product or COA
If you are a researcher handling either compound, here is what a legitimate certificate of analysis (COA) should contain and what the red flags are.
Minimum COA fields for a peptide:
- Purity by HPLC (high-performance liquid chromatography), stated as a percentage. For research-grade peptides, anything below 95% HPLC purity should be questioned. Cosmetic-grade standards are lower; pharmaceutical-grade is typically above 98%.
- Peptide content (not just mass). A vial labeled "5 mg" may contain 5 mg of material but only 3 mg of actual peptide if the rest is counterions, water, and residual solvent. Look for peptide content stated separately from gross weight.
- Molecular weight confirmation, typically by mass spectrometry (ESI-MS or MALDI). MT2 molecular weight is approximately 1024 Da; MT1 (afamelanotide) is approximately 1647 Da. If the mass spectrum does not match, the compound is not what it claims to be.
- Testing lab name and date. An undated COA or one from an unnamed in-house lab carries no independent verification.
Reconstitution math example (MT2): A 10 mg vial. You want a 1 mg/mL solution. Add 10 mL of bacteriostatic water. A 0.025 mg/kg dose for an 80 kg person is 2.0 mg, which is 2.0 mL of that solution. Check your math before any use; errors in peptide dosing are easy and consequential.
Signs of degraded product: Yellow-brown reconstituted solution (Trp oxidation), cloudy or particulate solution (aggregation or contamination), lyophilized cake that is wet, sticky, or collapsed rather than a fine white powder (moisture intrusion and partial hydrolysis).
FAQ
What is the core difference between MT1 and MT2?
MT1 (afamelanotide) is a linear, MC1R-selective analog used clinically for photoprotection. MT2 is a cyclic, non-selective analog that hits MC1R, MC3R, MC4R, and MC5R, producing stronger tanning, sexual arousal, and a broader side-effect profile.
Which is more effective for tanning, MT1 or MT2?
Both produce measurable pigmentation, but direct head-to-head RCTs are lacking. MT1 (afamelanotide) has the strongest controlled evidence from EPP trials. MT2's tanning is widely reported but rests on smaller or older studies with less rigorous design.
Does MT2 actually increase libido and erections?
Yes, via MC4R agonism in hypothalamic pathways. A placebo-controlled pilot by Wessells et al. (2000) in 10 men showed MT2 produced erections in 80% of participants vs 17% for placebo at a single 0.025 mg/kg subcutaneous dose. Effect was short-lived and came with nausea.
Is MT1 FDA-approved?
Afamelanotide (Scenesse), the implant form of MT1, received FDA approval in 2019 for erythropoietic protoporphyria (EPP). MT2 has no approved form anywhere; it remains a research compound.
What side effects does MT2 have that MT1 does not?
MT2's MC4R activity drives spontaneous erections, increased appetite suppression, and stronger nausea. Its MC3R and MC5R activity may affect energy balance and sebaceous glands. MT1 is far more receptor-selective and rarely causes these effects at clinical doses.
Can MT2 cause melanoma or worsen moles?
No controlled human data establish a causal link, but MC1R agonism stimulates melanocyte proliferation and existing nevi can darken. Regulators including the UK MHRA have issued warnings. Long-term carcinogenicity data in humans are absent; caution is warranted.
How do you store MT1 and MT2 peptides to prevent degradation?
Both are susceptible to oxidation and hydrolysis. Lyophilized powder should be kept at 2 to 8 degrees Celsius, away from light. Once reconstituted, use within days and keep refrigerated. MT2's cyclic lactam structure offers some protection against backbone hydrolysis compared to linear MT1, contributing to modestly better solution stability, but both degrade meaningfully at room temperature over days to weeks.
What is the half-life of MT1 vs MT2?
Afamelanotide implant releases drug slowly over roughly 60 days by design. Injectable afamelanotide has a plasma half-life of approximately 2 hours. MT2 half-life in human plasma is not well-characterized in published literature; animal data suggest rapid clearance in the range of 1 to 2 hours subcutaneously.
Is MT2 legal to buy?
Legality varies by country. In the US, MT2 is not FDA-approved and cannot be legally sold for human use. In the UK, the MHRA classifies it as an unlicensed medicine. It is widely sold online as a research chemical, which does not make it legal or safe for self-administration.
Which peptide is better studied, MT1 or MT2?
MT1 (afamelanotide) has significantly more human RCT data, including multiple phase 3 trials in EPP and vitiligo populations. MT2 has mostly early-phase or pilot human data, plus substantial animal literature.
Can you combine MT1 and MT2?
No published human data support combination use. Theoretically, additive MC1R stimulation could increase pigmentation but also raise the risk of melanocyte overstimulation. No safety data exist; combining them is not supported by evidence.
What does a degraded MT2 vial look like?
A degraded MT2 solution may appear yellow-brown instead of clear or faintly yellow, may have visible particulate matter, or may smell off. Lyophilized powder that has absorbed moisture clumps rather than appearing as a fine cake. Any of these signs indicate the product should be discarded.
Sources
- Langendonk JG et al. "Afamelanotide for erythropoietic protoporphyria." New England Journal of Medicine. 2015;373(1):48-59.
- Wessells H et al. "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction." Urology. 2000;56(4):641-646.
- Lim HW et al. "Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo." JAMA Dermatology. 2019;155(10):1132-1139.
- FDA. "Scenesse (afamelanotide) approval." NDA 210797. October 2019. FDA.gov.
- FDA. "Vyleesi (bremelanotide) approval." NDA 210557. June 2019. FDA.gov.
- Diamond LE et al. "A double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction." International Journal of Impotence Research. 2004;16(1):51-59.
- Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-930.
- MHRA. "Melanotan: do not use." Drug Safety Update. 2008. gov.uk/mhra.
- Cone RD. "Anatomy and regulation of the central melanocortin system." Nature Neuroscience. 2005;8(5):571-578.
- Haskell-Luevano C, Monck EK. "Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor." Regulatory Peptides. 2001;99(1):1-7.
Footer Disclaimers
Platform: FormBlends is an information and educational resource. This page does not constitute medical advice and does not create a patient-provider relationship.
Research Compound Notice: MT2 (Melanotan II) is not approved by the FDA or any comparable regulatory body for human use. It is classified as a research compound. Information provided on this page is for scientific and educational purposes only and does not endorse self-administration.
Results: Individual outcomes vary. The evidence summaries on this page reflect population-level trial data and do not predict individual response.
Trademark: Scenesse is a registered trademark of Clinuvel Pharmaceuticals. Vyleesi is a registered trademark of AMAG Pharmaceuticals. FormBlends is not affiliated with either company. All third-party trademarks are the property of their respective owners.